EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Beyond “Psychotropic”

Eric J Lenze, Angela M Reiersen, Charles F Zorumski, Paramala J Santosh

The Journal of Clinical Psychiatry · 2023

DOI: 10.4088/jcp.22r14494 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Psychiatry, 2023. Verfasst von Eric J Lenze und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri. Hauptthemen laut MEDLINE: Drug Repositioning, COVID-19, Alzheimer Disease, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance: "Psychotropic" drugs have widespread reach and impact throughout the brain and body. Thus, many of these drugs could be repurposed for non-psychiatric indications of high public health impact. Observations: The selective serotonin reuptake inhibitor (SSRI) fluvoxamine was shown efficacious as a COVID-19 treatment based on randomized controlled trials (RCTs), and a benefit of other antidepressants has been posited based on observational and preclinical studies. In this review, we illuminate features of SSRIs and other psychiatric drugs that make them candidates to repurpose for non-psychiatric indications. We summarize research that led to fluvoxamine's use in COVID-19 and provide guidance on how to use it safely. We summarize studies suggestive of benefit of other antidepressants versus COVID-19 and long COVID. We also describe putative mechanisms of psychiatric drugs in treating long COVID, Alzheimer's disease, cancer, and other conditions. Conclusion and Relevance: There is a potentially great clinical and public health impact of psychotropic drug repurposing. Challenges exist to such repurposing efforts, but solutions exist for researchers, regulators, and funders that overcome these challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningCOVID-19Alzheimer DiseaseNeoplasmsCOVID-19 Drug TreatmentMental DisordersPsychotropic DrugsHumansAnimalsFluvoxamineSelective Serotonin Reuptake InhibitorsPost-Acute COVID-19 Syndrome

Substanzen

FluvoxaminePsychotropic DrugsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.
  • Corresponding author: Eric Lenze, MD, 660 S Euclid Box 8134, St Louis, MO 63110 (lenzee@wustl.edu).
  • Department of Child and Adolescent Psychiatry, King's College London, London, United Kingdom.
  • Department of Child and Adolescent Mental Health, South London and Maudsley NHS Foundation Trust, London, United Kingdom.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Lenze, E. J., Reiersen, A. M., Zorumski, C. F., & Santosh, P. J. (2023). Beyond “Psychotropic”. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.22r14494

Vancouver

Lenze EJ, Reiersen AM, Zorumski CF, Santosh PJ. Beyond “Psychotropic”. The Journal of Clinical Psychiatry. 2023. doi:10.4088/jcp.22r14494

BibTeX
@article{Lenze2023,
  author = {Lenze, Eric J and Reiersen, Angela M and Zorumski, Charles F and Santosh, Paramala J},
  title = {Beyond “Psychotropic”},
  journal = {The Journal of Clinical Psychiatry},
  year = {2023},
  doi = {10.4088/jcp.22r14494}
}
Kostenlos starten →